Feinstein Institute of Medical Research, Zucker Hillside Hospital, Division of Psychiatry Research, Department of Psychiatry, North Shore-Long Island Jewish Health System, 75-59 263rd Street, Glen Oaks, NY 11004, USA.
Expert Opin Drug Metab Toxicol. 2013 Feb;9(2):183-91. doi: 10.1517/17425255.2013.736964. Epub 2012 Dec 1.
Antipsychotic drug is the mainstay of treatment for schizophrenia, and there are large inter-individual differences in clinical response and side effects. Pharmacogenetics provides a valuable tool to fulfill the promise of personalized medicine by tailoring treatment based on one's genetic markers.
This article reviews the recent progress in pharmacogenetic research of antipsychotic drugs since 2010, focusing on two areas: antipsychotic-induced weight gain and clozapine-induced agranulocytosis. The article also provides discussion on the important methodological issues in this area of research. The specific aim of this article is to provide the reader with up-to-date evidence in pharmacogenetic research, and for them to gain familiarity to the issues and challenges facing the field.
Pharmacogenetic studies of antipsychotic drugs are promising despite many challenges. Recent advances as reviewed in this article push the field closer to routine clinical utilization of pharmacogenetic testing. Progress in genomic technology and bioinformatics, larger sample sizes, better phenotype characterization, and careful consideration of study design issues will help to elevate antipsychotic pharmacogenetics to its next level.
抗精神病药物是治疗精神分裂症的主要方法，但临床反应和副作用存在很大的个体差异。药物遗传学提供了一个有价值的工具，可以根据个体的遗传标记来定制治疗，从而实现个性化医疗的承诺。
本文回顾了 2010 年以来抗精神病药物药物遗传学研究的最新进展，重点关注两个领域：抗精神病药引起的体重增加和氯氮平引起的粒细胞缺乏症。本文还讨论了该研究领域中重要的方法学问题。本文的具体目的是为读者提供药物遗传学研究的最新证据，并使他们熟悉该领域面临的问题和挑战。
尽管面临许多挑战，但抗精神病药物的药物遗传学研究仍有很大希望。本文回顾的最新进展使该领域更接近抗精神病药物药物遗传学检测的常规临床应用。基因组技术和生物信息学的进步、更大的样本量、更好的表型特征描述以及对研究设计问题的仔细考虑将有助于将抗精神病药物遗传学提升到一个新的水平。
